News >

IO/Targeted Combos Poised to Enter Metastatic Urothelial Carcinoma Paradigm

Jessica Hergert
Published: Thursday, Mar 26, 2020

Daniel P. Petrylak, MD

Daniel P. Petrylak, MD
The rapid influx of immunotherapy and targeted therapy approvals in metastatic urothelial carcinoma has led research efforts to pivot toward potentially enhancing response rates with combination regimens, said Daniel P. Petrylak, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication